Since CD24 can be expressed during early phases of B‐cell differentiation and both MCL and CLL share similar early B‐cell of origin,6, 15 blockade of CD24 DEMs could be a promising therapeutic approach to explore in this setting, since TAMs in MCL and NLCs in CLL are strictly interconnected with their corresponding tumoral cells, providing cancer proliferation and immune escape.2, 3, 4, 5, 6, 7, 8. This evidence concerns the gene CD24 and B-cell chronic lymphocytic leukemia.